Last reviewed · How we verify
NCT06841315
A Varegacestat Hepatic Impairment Study
Phase 1 trial testing varegacestat in Healthy Volunteer in 35 participants. Completed in 6 March 2026.
5 November 2025
Quick facts
| Lead sponsor | Immunome, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 35 |
| Start date | 7 March 2025 |
| Primary completion | 5 November 2025 |
| Estimated completion | 6 March 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- varegacestat — full drug profile →
Conditions studied
- Healthy Volunteer — all drugs for Healthy Volunteer →
- Hepatic Impairment (HI) — all drugs for Hepatic Impairment (HI) →
Sponsor
Immunome, Inc. — full company profile →
Who can join
Adults 18 to 84, any sex, with Healthy Volunteer or Hepatic Impairment (HI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06841315
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of varegacestat
Trials testing the same drug.
- NCT06845852 — A Phase 1 Mass Balance Study of Varegacestat · Phase 1 · completed
- NCT06855264 — A Cardiac Liability Study of Varegacestat in Healthy Participants · Phase 1 · completed
- NCT06677996 — A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healt · Phase 1 · completed
Other recruiting trials for Healthy Volunteer
Currently open trials in the same condition.
- NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
- NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
- NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
- NCT07439263 — Single Ascending Dose Study of HB2198 in Healthy Participants · Phase 1 · recruiting
- NCT07220122 — Impact of Exogenous Ketones on Breathing in Healthy Volunteers · EARLY_PHASE1 · recruiting
Other Immunome, Inc. trials
Trials by the same sponsor.
- NCT06845852 — A Phase 1 Mass Balance Study of Varegacestat · Phase 1 · completed
- NCT06855264 — A Cardiac Liability Study of Varegacestat in Healthy Participants · Phase 1 · completed
- NCT06677996 — A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healt · Phase 1 · completed
- NCT05429021 — IMM-BCP-01 in Mild to Moderate COVID-19 · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06841315 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Immunome, Inc.
- Last refreshed: 10 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06841315.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing